A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study is being conducted in participants with geographic atrophy (GA) secondary to
age-related macular degeneration (AMD) to determine if intravitreal (IVT) injections of
ANX007 reduce GA lesion growth rate. The results will be used to guide further development of
ANX007 in participants with geographic atrophy. The total duration of participation is
expected to be approximately 19 months.